| |
Total duration of follow up (patient years) |
¶ Hazard Ratio (95% CI) |
P Value |
| LPV/r |
267 |
1.69 (1.1 to 2.60) |
0.017 |
| ATZ/r |
562 |
1.52 (1.14 to 2.03) |
0.004 |
| DRV/r |
451 |
1.31 (0.94 to 1.81) |
0.108 |
| EFV |
1400 |
1 |
|
¶ adjusted for Gender, Age at start of HAART, ethnicity, baseline eGFR, baseline
CD4 count, baseline viral load, baseline Hepatitis C Antibody status, Hepatitis B
Surface Antigen status and prior exposure to tenofovir/indinavir and total duration
of tenofovir exposure
HAART highly active antiretroviral therapy NRTI nucleos(t)ide reverse
transcriptase inhibitor ATZ atazanavir DRV darunavir LPV lopinavir EFV efavirenz
r ritonavir eGFR estimated glomerular filtration rate |
